26 Jan, 2011
Eisai’s eritoran ACCESS study in severe sepsis does not meet primary endpoint
Posted by: admin In: News
Eisai’s eritoran ACCESS study in severe sepsis does not meet primary endpoint Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European [...]